CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission

Inclusion Criteria: * Documented informed consent of the participant * Agreement to allow the use of archival tissue from diagnostic tumor biopsies * If unavailable, exceptions may be granted with Study Principal Investigator (PI) approval * Note: For research participants who do not speak English, a short form consent may be used with a City of Hope (COH) certified interpreter/translator to proceed with screening and leukapheresis, while the request for a translated full consent is processed. However, the research participant is allowed to proceed with lymphodepletion and T cell infusion only after the translated full consent form is signed * Age: \>= 55 years * Eastern Cooperative Oncology Group (ECOG) \< 2 / Karnofsky Performance Status (KPS) \>= 70 * Ability to read and understand English for Questionnaires * Histologically confirmed CD19+ ALL at the time of diagnosis * In morphological first complete remission regardless of minimal residual disease (MRD) status * No immediate plan for transplant * Remission after induction +/- reinduction therapy * Fully recovered from the acute toxic effects (except alopecia) to =\< Grade 1 to prior anti-cancer therapy * Total bilirubin =\< 1.5 X upper limit of normal (ULN) (unless has Gilbert's disease) * Aspartate aminotransferase (AST) =\< 3 x ULN * Alanine transaminase (ALT) =\< 3 x ULN * Creatinine clearance of \>= 60 mL/min per 24 hour urine test or the Cockcroft-Gault formula * Left ventricular ejection fraction (LVEF) \>= …